1
|
Dumit S, Avtandilashvili M, McComish SL, Miller G, Swanson J, Tolmachev SY. Modeling Plutonium Decorporation in a Female Nuclear Worker Treated with Ca-DTPA after Inhalation Intake. HEALTH PHYSICS 2024:00004032-990000000-00170. [PMID: 39037363 DOI: 10.1097/hp.0000000000001859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/23/2024]
Abstract
ABSTRACT The present work models plutonium (Pu) biokinetics in a female former nuclear worker. Her bioassay measurements are available at the US Transuranium and Uranium Registries. The worker was internally exposed to a plutonium-americium mixture via acute inhalation at a nuclear weapons facility. She was medically treated with injections of 1 g Ca-DTPA on days 0, 5, and 14 after the intake. Between days 0 and 20, fecal and urine samples were collected and analyzed for 239Pu and 241Am. Subsequently, she was followed up for bioassay monitoring over 14 y, with additional post-treatment urine samples collected and analyzed for 239Pu. The uniqueness of this dataset is due to the availability of: (1) both early and long-term bioassay data from a female with plutonium intake; (2) data on chelation therapy for a female; and (3) fecal measurement results. Chelation therapy with Ca- and/or Zn-salts of DTPA is known to aid in reducing the internal radiation dose by enhancing the excretion of plutonium and americium from the body. Such enhancement affects plutonium biokinetics in the human body, posing a challenge to the internal dose assessment. The current radiation dose assessment practice is to exclude the data affected by Ca-DTPA from the analysis. The present analysis is the first to explicitly model the chelation-affected bioassay data in a female by using a newly developed chelation model. Thus, the bioassay data collected during and after the Ca-DTPA administrations were used for biokinetic modeling and dose assessment. The Markov Chain Monte Carlo method was used to investigate model parameter uncertainty, based on the bioassay data and assumed prior probability distributions. A χ2/nData (number of data points) ≈ 1 was observed in this study, which indicates self-consistency of the data with the model. Results of this study show that the worker's 239Pu intake was 12 Bq, with a committed effective dose to the whole-body of 1.2 mSv and a committed equivalent dose to the bone surfaces, liver, and lungs of 37.8, 9.1, and 0.8 mSv, respectively. This study also discusses the worker's dose reduction due to chelation treatment.
Collapse
Affiliation(s)
- Sara Dumit
- Los Alamos National Laboratory (LANL), Los Alamos, NM 87545
| | - Maia Avtandilashvili
- United States Transuranium and Uranium Registries (USTUR), College of Pharmacy and Pharmaceutical Sciences, Washington State University (WSU), Richland, WA 99354
| | - Stacey L McComish
- United States Transuranium and Uranium Registries (USTUR), College of Pharmacy and Pharmaceutical Sciences, Washington State University (WSU), Richland, WA 99354
| | | | | | - Sergey Y Tolmachev
- United States Transuranium and Uranium Registries (USTUR), College of Pharmacy and Pharmaceutical Sciences, Washington State University (WSU), Richland, WA 99354
| |
Collapse
|
2
|
Mate-Kole EM, Dewji SA. Mathematical complexities in radionuclide metabolic modelling: a review of ordinary differential equation kinetics solvers in biokinetic modelling. JOURNAL OF RADIOLOGICAL PROTECTION : OFFICIAL JOURNAL OF THE SOCIETY FOR RADIOLOGICAL PROTECTION 2024; 44:021001. [PMID: 38324906 PMCID: PMC11214694 DOI: 10.1088/1361-6498/ad270d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/24/2023] [Revised: 01/26/2024] [Accepted: 02/07/2024] [Indexed: 02/09/2024]
Abstract
Biokinetic models have been employed in internal dosimetry (ID) to model the human body's time-dependent retention and excretion of radionuclides. Consequently, biokinetic models have become instrumental in modelling the body burden from biological processes from internalized radionuclides for prospective and retrospective dose assessment. Solutions to biokinetic equations have been modelled as a system of coupled ordinary differential equations (ODEs) representing the time-dependent distribution of materials deposited within the body. In parallel, several mathematical algorithms were developed for solving general kinetic problems, upon which biokinetic solution tools were constructed. This paper provides a comprehensive review of mathematical solving methods adopted by some known internal dose computer codes for modelling the distribution and dosimetry for internal emitters, highlighting the mathematical frameworks, capabilities, and limitations. Further discussion details the mathematical underpinnings of biokinetic solutions in a unique approach paralleling advancements in ID. The capabilities of available mathematical solvers in computational systems were also emphasized. A survey of ODE forms, methods, and solvers was conducted to highlight capabilities for advancing the utilization of modern toolkits in ID. This review is the first of its kind in framing the development of biokinetic solving methods as the juxtaposition of mathematical solving schemes and computational capabilities, highlighting the evolution in biokinetic solving for radiation dose assessment.
Collapse
Affiliation(s)
- Emmanuel Matey Mate-Kole
- Nuclear and Radiological Engineering and Medical Physics Programs, Georgia Institute of Technology, Atlanta, GA, United States of America
| | - Shaheen Azim Dewji
- Nuclear and Radiological Engineering and Medical Physics Programs, Georgia Institute of Technology, Atlanta, GA, United States of America
| |
Collapse
|
3
|
Dumit S, Miller G, Grémy O, Poudel D, Bertelli L, Klumpp JA. Chelation Modeling of a Plutonium-238 Inhalation Incident Treated with Delayed DTPA. Radiat Res 2023; 200:577-586. [PMID: 37956868 DOI: 10.1667/rade-23-00135.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 10/14/2023] [Indexed: 11/15/2023]
Abstract
This work describes an analysis, using a previously established chelation model, of the bioassay data collected from a worker who received delayed chelation therapy following a plutonium-238 inhalation. The details of the case have already been described in two publications. The individual was treated with Ca-DTPA via multiple intravenous injections and then nebulizations beginning several months after the intake and continuing for four years. The exact date and circumstances of the intake are unknown. However, interviews with the worker suggested that the intake occurred via inhalation of a soluble plutonium compound. The worker provided daily urine and fecal bioassay samples throughout the chelation treatment protocol, including samples collected before, during, and after the administration of Ca-DTPA. Unlike the previous two publications presenting this case, the current analysis explicitly models the combined biokinetics of the plutonium-DTPA chelate. Using the previously established chelation model, it was possible to fit the data through optimizing only the intake (day and magnitude), solubility, and absorbed fraction of nebulized Ca-DTPA. This work supports the hypothesis that the efficacy of the delayed chelation treatment observed in this case results mainly from chelation of cell-internalized plutonium by Ca-DTPA (intracellular chelation). It also demonstrates the validity of the previously established chelation model. As the bioassay data were modified to ensure data anonymization, the calculation of the "true" committed effective dose was not possible. However, the treatment-induced dose inhibition (in percentage) was calculated.
Collapse
Affiliation(s)
- Sara Dumit
- Los Alamos National Laboratory (LANL), Radiation Protection Division, Los Alamos, New Mexico 87545
| | - Guthrie Miller
- Unaffiliated (retired from Los Alamos National Laboratory), Santa Fe, New Mexico
| | - Olivier Grémy
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Université Paris-Saclay, Fontenay-aux-Roses, France
| | - Deepesh Poudel
- Los Alamos National Laboratory (LANL), Radiation Protection Division, Los Alamos, New Mexico 87545
| | | | - John A Klumpp
- Los Alamos National Laboratory (LANL), Radiation Protection Division, Los Alamos, New Mexico 87545
| |
Collapse
|
4
|
Kastl M, Grémy O, Lamart S, Giussani A, Li WB, Hoeschen C. Modelling DTPA therapy following Am contamination in rats. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2023; 62:483-495. [PMID: 37831188 PMCID: PMC10628027 DOI: 10.1007/s00411-023-01046-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Accepted: 09/25/2023] [Indexed: 10/14/2023]
Abstract
A major challenge in modelling the decorporation of actinides (An), such as americium (Am), with DTPA (diethylenetriaminepentaacetic acid) is the fact that standard biokinetic models become inadequate for assessing radionuclide intake and estimating the resulting dose, as DTPA perturbs the regular biokinetics of the radionuclide. At present, most attempts existing in the literature are empirical and developed mainly for the interpretation of one or a limited number of specific incorporation cases. Recently, several approaches have been presented with the aim of developing a generic model, one of which reported the unperturbed biokinetics of plutonium (Pu), the chelation process and the behaviour of the chelated compound An-DTPA with a single model structure. The aim of the approach described in this present work is the development of a generic model that is able to describe the biokinetics of Am, DTPA and the chelate Am-DTPA simultaneously. Since accidental intakes in humans present many unknowns and large uncertainties, data from controlled studies in animals were used. In these studies, different amounts of DTPA were administered at different times after contamination with known quantities of Am. To account for the enhancement of faecal excretion and reduction in liver retention, DTPA is assumed to chelate Am not only in extracellular fluids, but also in hepatocytes. A good agreement was found between the predictions of the proposed model and the experimental results for urinary and faecal excretion and accumulation and retention in the liver. However, the decorporation from the skeletal compartment could not be reproduced satisfactorily under these simple assumptions.
Collapse
Affiliation(s)
- Manuel Kastl
- Institute of Radiation Medicine, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany.
| | - Olivier Grémy
- Laboratoire de Radio Toxicologie, CEA, Université de Paris-Saclay, Arpajon, France
| | - Stephanie Lamart
- Laboratoire de Radio Toxicologie, CEA, Université de Paris-Saclay, Arpajon, France
- Laboratoire d'Evaluation de la Dose Interne, Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SDOS/LEDI, Fontenay-aux-Roses, France
| | - Augusto Giussani
- Division of Medical and Occupational Radiation Protection, Federal Office for Radiation Protection, Oberschleißheim, Germany
| | - Wei Bo Li
- Institute of Radiation Medicine, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
- Division of Medical and Occupational Radiation Protection, Federal Office for Radiation Protection, Oberschleißheim, Germany
| | - Christoph Hoeschen
- Institut für Medizintechnik, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany
| |
Collapse
|
5
|
Tani K, Ishigure N, Kim E, Tominaga T, Tatsuzaki H, Akashi M, Kurihara O. Biokinetic model analysis with DTPA administration for a case of accidental inhalation of actinides in Japan. RADIATION PROTECTION DOSIMETRY 2023; 199:2025-2029. [PMID: 37819312 DOI: 10.1093/rpd/ncac224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Revised: 09/21/2022] [Accepted: 10/10/2022] [Indexed: 10/13/2023]
Abstract
Accidental inhalation intake of plutonium isotopes and 241Am occurred at a Pu research facility in Japan in 2017, and the five workers involved in this accident were treated by the administration of Ca/Zn-diethylenetriaminepentaacetic acid (DTPA). For the worker who was most internally exposed, the therapy was continued over 1 y after the accident. Urinary samples collected before and after each administration were subject to bioassay to evaluate the efficacy of the dose reduction. This study performed numerical analyses using a biokinetic model dealing with 241Am-DTPA with reference to the European Coordinated Network on Radiation Dosimetry approach, which assumes that the complex of actinides and Ca/Zn-DTPA is generated in the designated compartments in the biokinetic model. The results of the model prediction well captured the trend of the observed urinary excretion in the long-term bioassay and would be useful to evaluate the efficacy of the Ca/Zn-DTPA administration for the worker involved in the accident.
Collapse
Affiliation(s)
- Kotaro Tani
- Department of Radiation Measurement and Dose Assessment, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan
| | - Nobuhito Ishigure
- Department of Radiation Measurement and Dose Assessment, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan
| | - Eunjoo Kim
- Department of Radiation Measurement and Dose Assessment, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan
| | - Takako Tominaga
- Department of Radiation Emergency Medicine, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan
| | - Hideo Tatsuzaki
- Department of Radiation Emergency Medicine, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan
| | - Makoto Akashi
- Department of Radiation Emergency Medicine, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan
| | - Osamu Kurihara
- Department of Radiation Measurement and Dose Assessment, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan
| |
Collapse
|
6
|
Dumit S, Miller G, Poudel D, Bertelli L, Klumpp J. Chelation Model Validation: Modeling of a Plutonium-238 Inhalation Incident Treated with DTPA at Los Alamos National Laboratory. HEALTH PHYSICS 2023; 124:113-124. [PMID: 36625835 PMCID: PMC9803384 DOI: 10.1097/hp.0000000000001647] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
ABSTRACT Accidental inhalation of plutonium at the workplace is a non-negligible risk, even when rigorous safety standards are in place. The intake and retention of plutonium in the human body may be a source of concern. Thus, if there is a suspicion of a significant intake of plutonium, medical countermeasures such as chelation treatment may be administered to the worker. The present work aimed to interpret the bioassay data of a worker involved in an inhalation incident due to a glovebox breach at Los Alamos National Laboratory's plutonium facility. The worker was treated with intravenous injections of calcium salts of diethylenetriaminepentaacetic acid (DTPA) in an attempt to reduce the amount of plutonium from the body and therefore reduce the internal radiation dose. It is well known in the internal dosimetry field that the administration of chelation treatment poses additional challenges to the dose assessment. Hence, a recently developed chelation model was used for the modeling of the bioassay data. The objectives of this work are to describe the incident, model the chelation-affected and non-affected bioassay data, estimate the plutonium intake, and assess the internal radiation dose.
Collapse
Affiliation(s)
- Sara Dumit
- Los Alamos National Laboratory, Radiation Protection Division, Los Alamos, NM 87545
| | - Guthrie Miller
- Unaffiliated (retired from Los Alamos National Laboratory), Santa Fe, NM
| | - Deepesh Poudel
- Los Alamos National Laboratory, Radiation Protection Division, Los Alamos, NM 87545
| | - Luiz Bertelli
- Los Alamos National Laboratory, Radiation Protection Division, Los Alamos, NM 87545
| | - John Klumpp
- Los Alamos National Laboratory, Radiation Protection Division, Los Alamos, NM 87545
| |
Collapse
|
7
|
Poudel D, Dumit S, Bertelli L, Miller G, Macsik Z, Klumpp J. Dose Assessment Following a 238 Pu Inhalation Incident at Los Alamos National Laboratory. HEALTH PHYSICS 2023; 124:88-96. [PMID: 36318044 DOI: 10.1097/hp.0000000000001628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
A glovebox breach at the plutonium facility at Los Alamos National Laboratory potentially exposed 15 individuals to 238 Pu aerosols. One of the individuals (P0) received two 1-g intravenous DTPA treatments, one on the day of the intake and another the following day. Several urine samples were collected from the individuals involved in the incident. Particle size analysis on the PPE and solubility analysis of the particles on a filter sample were conducted in vitro. The applicability of the results from the in vitro studies for dose assessment was questionable because of the effect of the cloth mask the workers were wearing for COVID-related protection. Based on several considerations, including the effect of cloth masks on the "effective" particle size inhaled and the analysis of fecal-to-urine ratio, the default Type M 1 μm AMAD model was used to estimate intakes and doses. Using the urinary excretion data collected after 100 d post last chelation treatment, the committed effective dose, E(50), for P0 was calculated to be 5.2 mSv. For all others, the bioassay data were consistent with no intakes or very small intakes [corresponding to E(50) less than 0.1 mSv].
Collapse
Affiliation(s)
- Deepesh Poudel
- Radiation Protection Services, Los Alamos National Laboratory, Los Alamos, NM
| | - Sara Dumit
- Radiation Protection Services, Los Alamos National Laboratory, Los Alamos, NM
| | - Luiz Bertelli
- Radiation Protection Services, Los Alamos National Laboratory, Los Alamos, NM
| | | | - Zsuzsanna Macsik
- Nuclear and Radiochemistry, Los Alamos National Laboratory, Los Alamos, NM
| | - John Klumpp
- Radiation Protection Services, Los Alamos National Laboratory, Los Alamos, NM
| |
Collapse
|
8
|
Grémy O, Blanchin N, Miccoli L. Excretion of Pu-238 during Long-term Chelation Therapy by Repeated DTPA Inhalation. HEALTH PHYSICS 2022; 123:197-207. [PMID: 35613373 DOI: 10.1097/hp.0000000000001584] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
ABSTRACT An individual underwent an extensive diethylenetriaminepentaacetate (DTPA) chelation therapy that started several months after plutonium incorporation, most likely by inhalation of a soluble compound. After receiving multiple intravenous infusions of DTPA, the patient continued the treatment by pulmonary delivery of aerosolized DTPA. The purpose of the present work is to provide and discuss the bioassay data obtained during the DTPA aerosol therapy and compare them with those under the DTPA infusion therapy that have been largely interpreted elsewhere. As with DTPA given intravenously, each delayed DTPA inhalation increased the clearance of plutonium not only in urine but also in feces, thus demonstrating the ability to remove plutonium retained by extrapulmonary tissues. Also, the slow decline of increased plutonium urinary elimination together with enhanced fecal excretion are two features coherent with the contribution of intracellular chelation to overall decorporation. The therapeutic benefit of DTPA inhalation appeared lower than with DTPA infusion, most likely due to a lower amount of DTPA reaching the systemic compartments where plutonium chelation predominates. The results suggest that DTPA administration through aerosol could be an alternative to the invasive procedure using a needle, i.e., intravenous injection/infusion, when protracted decorporation therapy is needed following transuranic internalization. Indeed, the patient may be more inclined to undergo a chelation treatment for a longer period because taking DTPA by inhalation may make it less cumbersome and painful.
Collapse
Affiliation(s)
- Olivier Grémy
- CEA, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Université Paris-Saclay, Fontenay-aux-Roses, France
| | - Nicolas Blanchin
- CEA, Service de Santé au Travail, Saint-Paul-Lez-Durance, France
| | - Laurent Miccoli
- CEA, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Université Paris-Saclay, Fontenay-aux-Roses, France
| |
Collapse
|
9
|
Lai EPC, Li C. Actinide Decorporation: A Review on Chelation Chemistry and Nanocarriers for Pulmonary Administration. Radiat Res 2022; 198:430-443. [PMID: 35943882 DOI: 10.1667/rade-21-00004.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Accepted: 07/05/2022] [Indexed: 11/03/2022]
Abstract
Chelation is considered the best method for detoxification by promoting excretion of actinides (Am, Np, Pu, Th, U) from the human body after internal contamination. Chemical agents that possess carboxylic acid or hydroxypyridinonate groups play a vital role in actinide decorporation. In this review article, we provide considerable background details on the chelation chemistry of actinides with an aim to formulate better decorporation agents. Nanocarriers for pulmonary delivery represent an exciting prospect in the development of novel therapies for actinide decorporation that both reduce toxic side effects of the agent and improve its retention in the body. Recent studies have demonstrated the benefits of using a nebulizer or an inhaler to administer chelating agents for the decorporation of actinides. Effective chelation therapy with large groups of internally contaminated people can be a challenge unless both the agent and the nanocarrier are readily available from strategic national stockpiles for radiological or nuclear emergencies. Sunflower lecithin is particularly adept at alleviating the burden of administration when used to form liposomes as a nanocarrier for pulmonary delivery of diethylenetriamine-pentaacetic acid (DTPA) or hydroxypyridinone (HOPO). Better physiologically-based pharmacokinetic models must be developed for each agent in order to minimize the frequency of multiple doses that can overload the emergency response operations.
Collapse
Affiliation(s)
- Edward P C Lai
- Ottawa-Carleton Chemistry Institute, Department of Chemistry, Carleton University, Ottawa, ON K1S 5B6, Canada
| | - Chunsheng Li
- Radiation Protection Bureau, Health Canada, Ottawa, ON K1A 1C1, Canada
| |
Collapse
|
10
|
Grémy O, Blanchin N, Miccoli L. Interpretation of Enhanced Fecal and Urinary Plutonium Excretion Data under a 2-y Regular DTPA Treatment Started Months after Intake. HEALTH PHYSICS 2021; 121:494-505. [PMID: 34591820 PMCID: PMC8505154 DOI: 10.1097/hp.0000000000001458] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
ABSTRACT In a worker who had internalized plutonium, most likely through inhalation of a somewhat soluble compound, an extensive diethylenetriaminepentaacetate (DTPA) treatment regimen was initiated several months after contamination. Numerous radiotoxicological analyses were performed in both fecal and urinary specimens collected, sometimes for three consecutive days after DTPA administration. Activity measurements showed the continued effectiveness of DTPA intravenous infusions in removing plutonium from tissues of retention even if the treatment regimen started very belatedly after contamination. In the present case, the activity excreted through urine within the first 24-h after a DTPA infusion contributed only about half of that activity excreted within the first three days (i.e., the cumulative activity of the first three 24-h urine collections). In addition, the careful study of the data revealed that DTPA-induced excretion of plutonium via fecal pathway significantly contributed to the overall decorporation. The intracellular chelation of plutonium may be responsible for this enhanced excretion of activity in feces as well as for the delayed and sustained increased clearance of activity in urine. The authors would suggest that the occupational physicians offer to individuals who internalized moderately soluble or soluble plutonium compounds undergo a long-term DTPA treatment, especially when it is not initiated promptly after intake. Under this scenario, measurements of plutonium in successive urine and fecal collections after treatment should be required to get a better estimate of the therapeutic benefit. Also, intracellular chelation and fecal route should be taken into account for better interpretation of radiotoxicological data and modeling of plutonium kinetics under delayed DTPA treatment.
Collapse
Affiliation(s)
- Olivier Grémy
- CEA, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Université Paris-Saclay, Fontenay-aux-Roses, France
| | - Nicolas Blanchin
- CEA, Service de Santé au Travail, Saint-Paul-Lez-Durance, France
| | - Laurent Miccoli
- CEA, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Université Paris-Saclay, Fontenay-aux-Roses, France
| |
Collapse
|
11
|
Development of a New Chelation Model: Bioassay Data Interpretation and Dose Assessment after Plutonium Intake Via Wound and Treatment with DTPA: Erratum. HEALTH PHYSICS 2021; 120:459. [PMID: 33605636 DOI: 10.1097/hp.0000000000001414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
|
12
|
Klumpp J, Bertelli L, Dumit S, Gadd M, Poudel D, Waters TL. Response to a Skin Puncture Contaminated with 238Pu at Los Alamos National Laboratory. HEALTH PHYSICS 2020; 119:704-714. [PMID: 33196523 DOI: 10.1097/hp.0000000000001250] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The three principal pathways for intakes of plutonium are ingestion, inhalation, and contaminated wounds. In August 2018, a glovebox worker at Los Alamos National Laboratory (LANL) sustained a puncture from a thread of a braided steel cable contaminated with Pu. The puncture produced no pain, no blood, and little or no visible mark. As a result, the potential for a contaminated wound was not immediately recognized, and a wound count was not conducted until elevated urine bioassay results were received 12 d after the incident. This paper discusses the circumstances of the incident, along with the medical response and dose assessment, and a discussion of the risks and benefits of the medical interventions.
Collapse
Affiliation(s)
- John Klumpp
- Los Alamos National Laboratory, Radiation Protection Division, MS G761, Los Alamos, NM 87545
| | | | | | | | | | | |
Collapse
|